Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,194
Out of 5,135 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $37.44 | +12.18% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $190.82 | +96.52% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $83.40 | +37.89% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $82.29 | +11.80% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $25.46 | -52.87% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $10.52 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $76.23 | +18.06% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $249.35 | +8.28% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $121.00 | -43.80% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $15.20 | +196.05% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $112.51 | +144.42% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $17.56 | +110.71% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $72.80 | -17.58% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $76.28 | -54.12% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $258.07 | -68.61% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $37.44
Upside: +12.18%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $190.82
Upside: +96.52%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $83.40
Upside: +37.89%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $82.29
Upside: +11.80%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $25.46
Upside: -52.87%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $10.52
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $76.23
Upside: +18.06%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $249.35
Upside: +8.28%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $121.00
Upside: -43.80%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $15.20
Upside: +196.05%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $112.51
Upside: +144.42%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $17.56
Upside: +110.71%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $72.80
Upside: -17.58%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $76.28
Upside: -54.12%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $258.07
Upside: -68.61%